chitosan has been researched along with Hyperlipemia in 14 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (7.14) | 18.2507 |
| 2000's | 3 (21.43) | 29.6817 |
| 2010's | 7 (50.00) | 24.3611 |
| 2020's | 3 (21.43) | 2.80 |
| Authors | Studies |
|---|---|
| Basak, S; Ghosh, N; Gopal Sahoo, N; Karmakar, T; Wang, Y | 1 |
| Abd El Maksoud, AI; Abourehab, MAS; Ali, MA; El Hassab, MA; Eldehna, WM; Elebeedy, D; Ghanem, A; Ibrahim, MH; Kamaly, OA; Saleh, A | 1 |
| Koumaravelou, K; Sarathchandiran, I; Selvasudha, N | 1 |
| Chen, L; He, H; Jiang, Y; Luo, X; Wang, C; Wang, N; Wang, Q; Zhang, T | 1 |
| Jiang, Q; Wang, B; Wang, X; Xia, W; Xu, Y; Yang, S; Zhang, S | 1 |
| Bai, Y; Cao, H; Deng, X; Guo, J; Hu, C; Su, Z; Yang, D | 1 |
| Qin, C; Wang, L; Wang, Z; Yan, Y; Zhang, F; Zhang, Z | 1 |
| Cai, K; Chen, X; Ding, X; Hou, Y; Li, J; Liu, Y; Shen, X | 1 |
| Ahmed, TA; Kurakula, M | 1 |
| Guo, J; Hu, YM; Su, ZQ; Tao, Y; Zhang, HL | 1 |
| Amigone, JL; Ausar, SF; Beltramo, DM; Bianco, ID; Castagna, LF; Diaz, G; León, AE; Lescano, C; Masih, R; Morcillo, M; Ribotta, PD; Rubin, G; Vilaro Mainero, M | 1 |
| Hu, Y; Huang, X; Qiu, L; Wu, J; Xu, G | 1 |
| Chobot, V; Kremenák, J; Opletal, L | 1 |
| Peng, LH | 1 |
14 other study(ies) available for chitosan and Hyperlipemia
| Article | Year |
|---|---|
Targeting mangiferin loaded N-succinyl chitosan-alginate grafted nanoparticles against atherosclerosis - A case study against diabetes mediated hyperlipidemia in rat.
Topics: Alginates; Animals; Atherosclerosis; Chitosan; Diabetes Mellitus; Hyperlipidemias; Molecular Docking Simulation; Nanoconjugates; Nanoparticles; Particle Size; Rats; Spectroscopy, Fourier Transform Infrared; Xanthones | 2022 |
In Vivo and In Silico Investigation of the Anti-Obesity Effects of
Topics: Animals; Catalase; Chitosan; Diet, High-Fat; Hyperlipidemias; Inflammation; Male; Malondialdehyde; Obesity; Rats; Rats, Sprague-Dawley; Seeds; Superoxide Dismutase; Tea | 2022 |
Interaction pattern and
Topics: Administration, Oral; Animals; Chitosan; Cholesterol, Dietary; Delayed-Action Preparations; Disease Models, Animal; Drug Administration Schedule; Drug Carriers; Drug Compounding; Drug Liberation; Female; Humans; Hyperlipidemias; Mice; Molecular Docking Simulation; Nanoparticles; Particle Size; Proton Magnetic Resonance Spectroscopy; Simvastatin; Spectroscopy, Fourier Transform Infrared | 2019 |
Chitooligosaccharides Modulate Glucose-Lipid Metabolism by Suppressing SMYD3 Pathways and Regulating Gut Microflora.
Topics: Animals; Chitosan; Diabetes Mellitus, Type 2; Dysbiosis; Dyslipidemias; Gastrointestinal Microbiome; Glucose; Hep G2 Cells; Histone-Lysine N-Methyltransferase; Humans; Hydroxymethylglutaryl CoA Reductases; Hyperglycemia; Hyperlipidemias; Kidney; Lipid Metabolism; Lipogenesis; Liver; Male; Mice; Oligosaccharides | 2020 |
Transcriptome analysis of the effects of chitosan on the hyperlipidemia and oxidative stress in high-fat diet fed mice.
Topics: Adipose Tissue; Animals; Body Weight; Chitosan; Diet, High-Fat; Epididymis; Gene Expression Profiling; Gene Ontology; Hyperlipidemias; Lipids; Liver; Male; Mice; Mice, Inbred C57BL; Organ Size; Oxidative Stress | 2017 |
Therapeutic Effect of Chitooligosaccharide Tablets on Lipids in High-Fat Diets Induced Hyperlipidemic Rats.
Topics: Adipose Tissue; Adiposity; Animals; Biomarkers; Chitin; Chitosan; Diet, High-Fat; Disease Models, Animal; Gene Expression Regulation; Hyperlipidemias; Kidney; Lipid Metabolism; Lipids; Liver; Oligosaccharides; Oxidation-Reduction; Rats; Tablets | 2019 |
Lipid-lowering activities of chitosan and its quaternary ammonium salt for the hyperlipidemia rats induced by high-fat diets.
Topics: Animals; Chitosan; Diet, High-Fat; Hyperlipidemias; Hypolipidemic Agents; Lipase; Lipids; Liver; Male; Oxidative Stress; Quaternary Ammonium Compounds; Rats; Rats, Sprague-Dawley | 2019 |
Recyclable heparin and chitosan conjugated magnetic nanocomposites for selective removal of low-density lipoprotein from plasma.
Topics: Adsorption; Biocompatible Materials; Blood Component Removal; Chitosan; Heparin; Humans; Hyperlipidemias; Lipoproteins, LDL; Magnetic Phenomena; Magnetite Nanoparticles; Materials Testing; Nanocomposites; Particle Size; Recycling | 2014 |
Co-Delivery of Atorvastatin Nanocrystals in PLGA based in situ Gel for Anti-Hyperlipidemic Efficacy.
Topics: Anticholesteremic Agents; Atorvastatin; Chemistry, Pharmaceutical; Chitosan; Drug Carriers; Drug Liberation; Gels; Hyperlipidemias; Lactic Acid; Nanoparticles; Particle Size; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Solvents; Surface Properties; X-Ray Diffraction | 2016 |
Hypolipidemic effects of chitosan nanoparticles in hyperlipidemia rats induced by high fat diet.
Topics: Animals; Blood Viscosity; Chitosan; Dietary Fats; Disease Models, Animal; Hyperlipidemias; Hypolipidemic Agents; Lipids; Male; Nanoparticles; Particle Size; Rats; Rats, Sprague-Dawley; Superoxide Dismutase; Toxicity Tests, Acute | 2011 |
Improvement of HDL- and LDL-cholesterol levels in diabetic subjects by feeding bread containing chitosan.
Topics: Blood Glucose; Body Weight; Bread; Chitin; Chitosan; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Food Additives; Glycated Hemoglobin; Humans; Hyperlipidemias; Treatment Outcome; Triglycerides | 2003 |
Mechanism study of chitosan on lipid metabolism in hyperlipidemic rats.
Topics: Animals; Anticholesteremic Agents; Bile Acids and Salts; Cellulose; Chitosan; Cholesterol; Feces; Hyperlipidemias; Lipid Metabolism; Lipids; Lipoproteins; Liver; Male; Organ Size; Rats; Rats, Sprague-Dawley; Receptors, LDL; RNA, Messenger; Triglycerides | 2007 |
[Phytotherapeutic aspects of diseases of the circulatory system. 4. Chitin and chitosan].
Topics: Anticholesteremic Agents; Chitin; Chitosan; Humans; Hyperlipidemias; Thrombosis | 1995 |
Article: In the absence of dietary surveillance, chitosan does not reduce plasma lipids...(SC Ho, et al)(SMJ Vol 42 Issue 1 January 2001.
Topics: Chitin; Chitosan; Clinical Trials as Topic; Humans; Hyperlipidemias; Lipids; Reproducibility of Results; Sample Size | 2001 |